Free Trial

Intra-Cellular Therapies (ITCI) Competitors

$65.62
+0.08 (+0.12%)
(As of 05/28/2024 ET)

ITCI vs. VIE, RARX, AIMT, KURA, IRWD, ALNY, TEVA, GMAB, RPRX, and BGNE

Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Viela Bio (VIE), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Kura Oncology (KURA), Ironwood Pharmaceuticals (IRWD), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BeiGene (BGNE).

Intra-Cellular Therapies vs.

Intra-Cellular Therapies (NASDAQ:ITCI) and Viela Bio (NASDAQ:VIE) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.

Intra-Cellular Therapies currently has a consensus target price of $90.17, suggesting a potential upside of 37.41%. Given Intra-Cellular Therapies' higher probable upside, research analysts plainly believe Intra-Cellular Therapies is more favorable than Viela Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intra-Cellular Therapies
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Viela Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Intra-Cellular Therapies received 502 more outperform votes than Viela Bio when rated by MarketBeat users. Likewise, 67.38% of users gave Intra-Cellular Therapies an outperform vote while only 40.00% of users gave Viela Bio an outperform vote.

CompanyUnderperformOutperform
Intra-Cellular TherapiesOutperform Votes
504
67.38%
Underperform Votes
244
32.62%
Viela BioOutperform Votes
2
40.00%
Underperform Votes
3
60.00%

In the previous week, Intra-Cellular Therapies had 7 more articles in the media than Viela Bio. MarketBeat recorded 7 mentions for Intra-Cellular Therapies and 0 mentions for Viela Bio. Intra-Cellular Therapies' average media sentiment score of 0.88 beat Viela Bio's score of 0.00 indicating that Intra-Cellular Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Intra-Cellular Therapies Positive
Viela Bio Neutral

Intra-Cellular Therapies has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Viela Bio has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$464.37M14.92-$139.67M-$1.16-56.57
Viela Bio$50M58.26-$86.43M-$7.02-7.55

Viela Bio has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -21.57%. Intra-Cellular Therapies' return on equity of -18.49% beat Viela Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Intra-Cellular Therapies-21.57% -18.49% -15.26%
Viela Bio N/A -33.97%-31.49%

92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 3.4% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Intra-Cellular Therapies beats Viela Bio on 12 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ITCI vs. The Competition

MetricIntra-Cellular TherapiesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.93B$6.72B$5.00B$8.09B
Dividend YieldN/A2.77%2.74%3.96%
P/E Ratio-56.5722.09176.4818.43
Price / Sales13.52239.902,386.6172.31
Price / CashN/A20.5033.0728.77
Price / Book10.675.854.944.39
Net Income-$139.67M$139.81M$104.35M$213.55M
7 Day Performance-2.06%-0.82%-0.63%-0.80%
1 Month Performance-10.43%3.07%3.85%3.42%
1 Year Performance9.00%-2.29%5.47%7.53%

Intra-Cellular Therapies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIE
Viela Bio
0 of 5 stars
$53.01
flat
N/AN/A$2.91B$50M-7.55166
RARX
Ra Pharmaceuticals
0 of 5 stars
$47.99
flat
N/A+0.0%$2.27B$3M-20.7772News Coverage
AIMT
Aimmune Therapeutics
0 of 5 stars
$34.49
flat
N/AN/A$2.26BN/A-7.68228
KURA
Kura Oncology
3.4698 of 5 stars
$21.49
+1.5%
$27.94
+30.0%
+61.0%$1.61BN/A-9.90142Positive News
IRWD
Ironwood Pharmaceuticals
4.1119 of 5 stars
$5.88
-1.2%
$18.40
+212.9%
-45.6%$931.35M$413.55M-0.87267Short Interest ↑
Analyst Revision
ALNY
Alnylam Pharmaceuticals
4.5014 of 5 stars
$150.06
+1.6%
$216.19
+44.1%
-20.3%$18.69B$2.00B-55.992,100Positive News
TEVA
Teva Pharmaceutical Industries
0.6743 of 5 stars
$16.77
+1.0%
$14.75
-12.0%
+125.0%$18.61B$15.85B-40.8937,851
GMAB
Genmab A/S
3.1027 of 5 stars
$28.01
+0.0%
$48.50
+73.2%
-31.0%$18.51B$2.39B23.342,204Short Interest ↑
RPRX
Royalty Pharma
4.798 of 5 stars
$26.64
+0.1%
$46.75
+75.5%
-17.7%$15.90B$2.36B19.8851Positive News
BGNE
BeiGene
2.6384 of 5 stars
$153.11
+0.3%
$251.93
+64.5%
-35.4%$14.65B$2.76B-20.2310,600Short Interest ↓
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:ITCI) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners